Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
John Farley MD
To examine the tumor response rate of patients on AZD6244 (NSC #748727).
To examine the acute toxicity of AZD6244 (NSC #748727) during the first course of treatment using CTCAE version 3.0.
To define the pharmacokinetic profile for AZD6244, 100 mg administered orally twice daily.
Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.